Nebivolol

Nebivolol, the active ingredient in Nebivolol, is a beta blocker (selective β1 adrenergic antagonist) presented as an oral tablet for oral use. It is indicated for the treatment of hypertension and chronic heart failure in adult patients. GNH USA supplies Nebivolol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is used in cardiovascular therapy to lower blood pressure and improve heart function. - Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications. - Chronic heart failure: improves ventricular performance and reduces symptoms such as dyspnea and fatigue. - Left ventricular systolic dysfunction: supports cardiac output and may decrease hospitalization risk.

Nebivolol may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Dizziness or light‑headedness: especially after the first dose or dose increase. - Fatigue or tiredness: may improve with continued therapy. - Nausea or mild gastrointestinal upset. - Bradycardia: heart rate reduction below 60 bpm in some patients.

Serious or Rare Side Effects: - Severe bradycardia or heart block requiring medical attention. - Marked hypotension leading to syncope. - Bronchospasm or worsening of asthma symptoms. - Allergic reactions such as rash, angioedema, or anaphylaxis. - Worsening heart failure or pulmonary edema.

Before initiating Nebivolol, clinicians should assess cardiovascular status and comorbid conditions. - Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Cardiac function evaluation: baseline ECG and ejection fraction assessment are recommended. - Respiratory caution: use carefully in patients with asthma or chronic obstructive pulmonary disease. - Renal or hepatic impairment: dose adjustment may be required based on clinical judgment. - Discontinuation: avoid abrupt cessation; taper gradually to reduce rebound hypertension. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid): - Other β‑blockers: additive bradycardia and hypotension. - Potent CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): increase nebivolol plasma levels. - Non‑dihydropyridine calcium‑channel blockers (verapamil, diltiazem): may cause severe bradycardia. - Antiarrhythmic agents (amiodarone, sotalol): heightened risk of conduction disturbances.

Moderate Interactions (Monitor Closely): - Diuretics: monitor electrolytes and blood pressure for additive effects. - ACE inhibitors or ARBs: watch for excessive hypotension. - Digoxin: observe for bradycardia. - NSAIDs: may blunt antihypertensive response. - Clonidine: risk of rebound hypertension if stopped abruptly.